Ofloxacin penetration into tuberculous pleural effusion

Yew, Wing Wai; Lee, J; Chan, C. Y.; Cheung, S.W.; Wong, Puisan; Kwan, Susan

doi:10.1128/aac.35.10.2159

Cited by 11 publications

(2 citation statements)

References 11 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…or p.o., to volunteers or patients with normal renal function (1,5). Previous studies have not shown any change in the bioavailability of ofloxacin in infectious disease patients versus normal volunteers (1,2,6,7,11,13,14). The bioavailability of ofloxacin has been previously investigated after administration of single doses (5,15), but to our knowledge this is the first study that has investigated it under steady-state conditions.…”

Section: Methodsmentioning

confidence: 88%

Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers

Flor¹,

Rogge²,

Chow³

1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The bioequivalence of oral and intravenous ofloxacin was investigated after the administration of multiple doses of 400 mg every 12 h to 20 healthy male volunteers in a randomized, crossover, open-label study. Ofloxacin concentrations in plasma were evaluated after 4 days of oral or intravenous (1-h infusion) dosing with a 3-day wash-out period between regimens. As expected, delivery to the systemic circulation took slightly longer after the oral dosing (time to maximum concentration of drug in serum of 1.7 h) relative to the 1-h intravenous infusion, but the systemic availabilities of ofloxacin by the two routes of administration were equivalent (area under the concentration-time curve from 0 to 12 h ratio of 95%). Since previous studies have not demonstrated any change in the bioavailability of ofloxacin in infectious disease patients, this study supports the interchangeability of these dosing regimens.Ofloxacin is a synthetic carboxyquinolone antimicrobial agent with potent broad-spectrum bactericidal activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria (8 Washout was performed during days 6 to 8. On day 9, the crossover took place and subjects again received p.o. or i.v. ofloxacin (400 mg ql2h) during days 9 to 12. On day 13, they received the last p.o. or i.v. morning dose. All subjects entered the study center at least 12 h prior to administration of the first dose and remained at the center until the last procedure was completed. Subjects were not allowed to eat within 2 h of a dose. For the morning doses, subjects fasted from at least midnight of the previous day. On days 5 and 13, food was not consumed after the prior evening meal until 2 h after the morning dose. Venous blood samples (5 ml) were drawn from each volunteer immediately prior to each dose on days 1, 3, 4, 9, 11, and 12. On days 5 and 13, blood samples were drawn immediately prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 16, and 24 h after dosing began.Analytical procedures. Plasma samples were analyzed for ofloxacin by a sensitive and specific high-pressure liquid chromatographic method previously described (3). After extraction at pH 7 with dichloromethane, the extract was injected onto a C18 ,uBondapak column (25 cm by 4.6 mm [inner diameter]; Waters Associates Inc., Milford, Mass.). The mobile phase consisted of 1.74 g of potassium dihydrogen phosphate and 20 mg of 1-hexanesulfonic sodium salt (Eastman Kodak Co., Rochester, N.Y.) dissolved in 650 ml of distilled water, combined with 350 ml of methanol, and adjusted to pH 3 with phosphoric acid. The imidazolic derivative of ofloxacin (Daiichi Seiyaku) was used as the internal standard. Detection was done with a UV detector at 313 nm. The limit of quantitation was 0.01 mg/liter, and the extraction efficiency was more than 75%. The assay was linear over the concentration range of 0.025 to 9 mg/liter. The intra-and interday coefficients of variation ranged from 3 to 6% over the standard curve concentration range of 0.025 to 9 mg/liter.

show abstract

Section: Methodsmentioning

confidence: 88%

Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers

Flor¹,

Rogge²,

Chow³

1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Since effective TB therapy began, strains of M. tuberculosis have acquired resistance to various drugs. Most ominously, the rising prevalence of MDR strains has resulted in many cases of marginally treatable, and often fatal disease [4].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Low-Dose Ofloxacin in the Treatment of Multidrug-Resistant Tuberculosis in Indonesia

Mangunnegoro

Hudoyo

1999

Chemotherapy

View full text Add to dashboard Cite

There is growing concern, even among developed countries, about the increasing incidence of tuberculosis that is resistant to both isoniazid and rifampicin. Results are reported herein from a study investigating ofloxacin in the treatment of 58 patients with multidrug-resistant tuberculosis (MDR-TB). Patients received ofloxacin 400 mg/day accompanied by three other anti-TB drugs to which there was in vitro susceptibility. Treatment duration was nine months. Of 50 evaluable patients, our results showed that bacterial conversion as assessed by sputum microscopy occurred in 23 patients (46%) at three months of therapy, in 36 (72%) at six months, and in 39 (78%) at the end of nine months of therapy. Culture negativity was found in 36 patients (72%) at nine months of therapy. Relapses occurred in four of 36 patients (11%) who achieved culture negativity at the end of the treatment period. Ofloxacin 400 mg in combination with other active anti-TB medications shows promising results in the treatment of MDR-TB in Indonesian patients.

show abstract

Role of Antimicrobial Peptides in Treatment and Prevention of Mycobacterium Tuberculosis: A Review

Mehta

Sharma

Mujawar

et al. 2022

Int J Pept Res Ther

View full text Add to dashboard Cite

Ofloxacin penetration into tuberculous pleural effusion

Cited by 11 publications

References 11 publications

Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers

Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers

Efficacy of Low-Dose Ofloxacin in the Treatment of Multidrug-Resistant Tuberculosis in Indonesia

Role of Antimicrobial Peptides in Treatment and Prevention of Mycobacterium Tuberculosis: A Review

Contact Info

Product

Resources

About